Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

Rhea-AI Summary

Decoy Therapeutics (Nasdaq: DCOY) announced that its intellectual property portfolio for Designable Multi-Antivirals (D-MAVs™) and the IMP³ACT™ design platform now includes seven patent families. The portfolio comprises one granted U.S. patent and 19 pending applications across the United States, Australia, Canada, China, Europe, Japan, and New Zealand.

According to Decoy Therapeutics, these patents and applications, all solely owned by the company, cover antiviral peptide conjugate compositions, automated flow manufacturing methods and linker chemistries, formulations, engineered D-MAVs targeting conserved class I viral fusion features, uses against multiple paramyxoviruses, and newly filed methods for designing class I fusion peptides underlying the IMP³ACT platform.

Positive

• Seven patent families now cover D-MAVs and IMP³ACT platform IP
• 19 pending patent applications filed across seven major jurisdictions
• One granted U.S. patent protecting antiviral peptide conjugates
• All patents and applications are solely owned by Decoy Therapeutics
• Broadly filed manufacturing patent family pending in six non-U.S. jurisdictions

Negative

• None.

Market Context

Historical reactions ranged from -25.79% for news_id 1087178 to 73.79% for news_id 1075414. That rec...

Analysis

Historical reactions ranged from -25.79% for news_id 1087178 to 73.79% for news_id 1075414. That record adds variability to an IP-focused announcement; the company’s pre-clinical status remains a key risk to monitor.

Key Figures

Patent families: 7 patent families Pending applications: 19 pending applications Granted patents: 1 granted U.S. patent +3 more

6 metrics

Patent families 7 patent families Current intellectual property portfolio

Pending applications 19 pending applications Filed across seven jurisdictions

Granted patents 1 granted U.S. patent Current portfolio

Jurisdictions 7 jurisdictions United States, Australia, Canada, China, Europe, Japan, and New Zealand

U.S. patent number 12,226,474 Methods and Compositions for Treating Infections

Newest filing date June 2026 Design methods behind the IMP3ACT platform

Historical Context

5 past events · Latest: Jul 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 27	In vitro data	Positive	-25.8%	Lead candidate showed in vitro activity against Ebola Zaire and Lassa fever viruses.
Jul 15	Board election	Positive	+7.5%	Stockholders elected Patricia Gauthier as a Class II director.
Jun 26	Private placement	Positive	+73.8%	Company announced up to $21 million in potential private-placement proceeds.
Jun 08	Investor presentation	Neutral	-5.5%	CEO was scheduled to discuss clinical development and the antiviral pipeline.
Jun 03	Board nomination	Positive	-7.4%	Company nominated Patricia Gauthier for election to its Class II board seat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news reactions were mixed, with three positive or neutral announcements followed by negative price reactions and two followed by positive reactions.

Key Terms

d-amino acids, antiviral peptide conjugates, automated flow peptide synthesis, class i viral fusion proteins

4 terms

d-amino acids medical

"viral spike protein sequences that include D-amino acids"

D-amino acids are mirror-image forms of the common building blocks of proteins; like left- and right-handed versions of the same molecule, they have the same atoms arranged in a flipped orientation. They matter to investors because their presence or use can change how a drug behaves, how long it lasts in the body, or serve as biomarkers in diagnostics, affecting product development, regulatory review, manufacturing complexity, and potential market value.

antiviral peptide conjugates medical

"claims antiviral peptide conjugates comprised of one or more"

Antiviral peptide conjugates are short chains of amino acids with virus-fighting activity that are chemically linked to another molecule—such as a carrier, polymer, lipid, or small drug—to improve stability, delivery into cells, targeting, or duration of action. Think of them as a therapeutic package with a labeled delivery tag that helps the active peptide reach and affect viruses more effectively; investors watch them because the linkage can change clinical performance, manufacturing complexity, patent value, and regulatory risk.

automated flow peptide synthesis technical

"directed to automated flow peptide synthesis methods"

A laboratory method that uses machines to build short chains of amino acids (peptides) by adding one building block at a time in a programmed, continuous or semi-continuous flow of reagents. Like an automated assembly line for molecules, it speeds up production, improves consistency, and makes it easier to scale and test many variants rapidly, which matters to investors because it can shorten development timelines and affect manufacturing costs and capacity for peptide-based drugs or diagnostics.

class i viral fusion proteins medical

"designed against conserved features of class I viral fusion proteins"

Class I viral fusion proteins are virus surface proteins that act like spring-loaded molecular tools to join the virus membrane with a host cell membrane, enabling viral entry. They undergo a dramatic shape change from a stable 'prefusion' form to a 'postfusion' form and are common targets for vaccines, antibodies, and antiviral drugs, so their structure and behavior are important to investors assessing biotech pipelines and regulatory prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform behind them

CAMBRIDGE, Mass., Aug. 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced continued expansion of its intellectual property portfolio, which now comprises seven patent families covering compositions of matter, methods of manufacture, formulations, and the company's IMP³ACT™ design platform.

The portfolio includes one granted U.S. patent and 19 pending applications filed in the United States, Australia, Canada, China, Europe, Japan, and New Zealand. All patents and applications are solely owned by Decoy.

"Our IP position has grown alongside the science," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "The early filings protected our first conjugates. The newer families protect the engineered sequences our platform now designs, the methods we use to make them, and the platform itself. That progression is one of the clearest external record of how far the technology has come."

Pending Applications

Granted patent. U.S. Patent No. 12,226,474, "Methods and Compositions for Treating Infections," claims antiviral peptide conjugates comprised of one or more viral spike protein sequences that include D-amino acids.

Manufacturing. "Methods for Making Peptide Conjugates and the Product Made Therefrom" is directed to automated flow peptide synthesis methods and linker chemistries applied to Decoy antiviral peptide conjugates. It is Decoy's most broadly filed family, pending in six jurisdictions outside the United States.

Engineered D-MAVs. "New Antiviral Therapeutic Peptides, Conjugates and Methods of Use Thereof" is directed to compounds designed against conserved features of class I viral fusion proteins, extending beyond wild-type peptide sequences. Companion filings are directed to formulations containing these conjugates and the use of said conjugates to interrupt transmission and extends to paramyxoviruses including measles, mumps, human parainfluenza virus, and Nipah.

Platform. Decoy's newest filing, "Method of Designing New Class I Fusion Peptides and Therapeutics Made Thereof," was filed in June 2026 and is directed to the design methods behind the IMP³ACT platform. It has not yet published.

About Decoy Therapeutics

Decoy Therapeutics is a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), a new category of antivirals engineered to target shared viral mechanisms, enabling a single, adaptable drug to work across many viruses. Built on the proprietary IMP³ACT platform, which combines AI-enabled design and rapid synthesis, Decoy develops peptide antivirals designed to move faster toward the clinic and expand what is possible in viral prevention and treatment. The company's lead candidates target many respiratory viruses, addressing the health and societal burden of viral disease.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "can," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that pending patent applications will not be granted, the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP³ACT^™ platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected.

Business Development
Peter Marschel, CBO
Peter@decoytx.com
617-943-6305

Media Relations
Tara Mulloy, TMC Studio
tara@tmc-studio.com
978-855-5219

View original content to download multimedia:https://www.prnewswire.com/news-releases/decoy-therapeutics-expands-intellectual-property-portfolio-covering-designable-multi-antivirals-and-the-impact-platform-302841187.html

SOURCE Decoy Therapeutics, Inc

FAQ

What did Decoy Therapeutics (Nasdaq: DCOY) announce about its patent portfolio on August 3, 2026?

Decoy Therapeutics announced expansion of its intellectual property portfolio to seven patent families, including one granted U.S. patent and 19 pending applications. According to Decoy Therapeutics, these cover D-MAV™ antiviral peptide conjugates, manufacturing methods, formulations, engineered sequences, and the IMP³ACT™ design platform across seven global jurisdictions.

How many patents and pending applications does Decoy Therapeutics (DCOY) now have for its D-MAVs and IMP³ACT platform?

Decoy Therapeutics reports one granted U.S. patent and 19 pending applications across seven jurisdictions within seven patent families. According to Decoy Therapeutics, these families protect compositions of matter, automated flow synthesis methods, linker chemistries, formulations, engineered D-MAVs, and the IMP³ACT design platform.

Which diseases and viral targets are covered by Decoy Therapeutics’ expanded patent filings for D-MAVs (DCOY)?

The expanded patent families include compounds designed against conserved features of class I viral fusion proteins. According to Decoy Therapeutics, companion filings extend to formulations and use of these conjugates to interrupt transmission, including applications to paramyxoviruses such as measles, mumps, human parainfluenza virus, and Nipah.

What is covered by Decoy Therapeutics’ granted U.S. patent No. 12,226,474 for D-MAVs (Nasdaq: DCOY)?

U.S. Patent No. 12,226,474 covers antiviral peptide conjugates comprising one or more viral spike protein sequences including D-amino acids. According to Decoy Therapeutics, this patent is titled “Methods and Compositions for Treating Infections” and protects key D-MAV™ conjugate constructs in the United States.

How does the IMP³ACT™ platform feature in Decoy Therapeutics’ latest intellectual property filings (DCOY)?

Decoy’s newest filing, submitted in June 2026, covers methods for designing new class I fusion peptides and related therapeutics. According to Decoy Therapeutics, this application captures the design methods behind the IMP³ACT™ platform, although the filing has not yet been published.

In which countries has Decoy Therapeutics filed pending D-MAV™ patent applications under symbol DCOY?

Decoy Therapeutics reports 19 pending patent applications for its D-MAVs and related technologies in the United States, Australia, Canada, China, Europe, Japan, and New Zealand. According to Decoy Therapeutics, one manufacturing-focused family is its most broadly filed outside the United States.